Compliance Status
Doubtful
Screened on Oct 19, 2026 · AAOIFI Standard 21
Acceptable
Is Regeneron Pharmaceuticals, Inc. (REGN) halal? Doubtful. Based on AAOIFI screening, Regeneron Pharmaceuticals, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 65/100 (Grade: B).
Quote this verdict
HalalScreener rates Regeneron Pharmaceuticals, Inc. (REGN) Doubtful, 65/100, grade B under AAOIFI Standard 21, screened Oct 19, 2026. Source: https://halalscreener.app/en/stock/REGN
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
You may own REGN, with caution
Its numbers sit close to AAOIFI limits. Cautious investors may prefer alternatives or ask a scholar first.
Purification amount is Pro
We have screened REGN's prohibited income, but the exact share you would need to purify is part of Pro.
REGN: Is Regeneron Pharmaceuticals, Inc. Halal?
Regeneron Pharmaceuticals, Inc.
$790.74
-0.70%
Market Cap: 81.4B
Get an email if REGN's halal status changes
We re-screen Regeneron Pharmaceuticals, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Sector: Healthcare · Industry: Biotechnology
Why This Stock Is Doubtful
- Income from prohibited sources is close to the 5% limit.
Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.
Shariah Compliance Status
See which ratio caused the failure.
See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.
AI Compliance Insight
PROInstitutional-grade Shariah analysis
See why REGN is rated Doubtful with institutional-grade analysis
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
Compliance History
Doubtfulnow
since Aug 2026
Halal
until the change above
Not Halal
until the change above
Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Know the day REGN's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Regeneron Pharmaceuticals, Inc. (REGN) halal to invest in?
Why did Regeneron Pharmaceuticals, Inc. get a B compliance rating?
What could change Regeneron Pharmaceuticals, Inc.'s Shariah verdict?
How often is Regeneron Pharmaceuticals, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.